, Volume 9, Issue 1, pp 38–43 | Cite as

Blockade of Metabotropic GABA-B Receptors as an Approach to Reduce Toxic Peripheral Effects of Cholinesterase Inhibitors

  • O. A. Lenina
  • P. Masson
  • K. A. PetrovEmail author


The application of organophosphate (OP) pesticides in agriculture, in addition to the existence of chemical warfare nerve agents and their possible use in terrorist acts is a significant threat to populations all over the world. Moreover, treatment of OP poisoning is still imperfect. Here, we studied the effect of blockade of metabotropic GABA-B receptors by compound CGP55845 (10 μM) on the force of muscle contractions when cholinesterases are inhibited by paraoxon. It was shown that CGP55845 prevented the decrease in the force of diaphragm muscle contractions caused by paraoxon ex vivo. Moreover, for in vivo experiments, GABA-B receptor blocker CGP36742 at the doses 30 and 100 mg/kg was used. It was shown that CGP36742 is able to reduce the lethality of mice after OP challenge. Thus, GABA-B receptor blockers can be considered as additional medications, which can complement the current therapy of acute poisoning by cholinesterase inhibitors.


Organophosphorus compounds Acetylcholinesterase inhibitors Neuromuscular junction GABA-B receptors 







γ-aminobutyric acid




Neuromuscular junction


Organophosphorus agents




Funding Information

Muscle contraction studies in this research were supported by Russian Science Foundation project no. 17-14-01097 for P.M. Toxicological studies were supported by the Program for “Basic Research for Biomedical Technologies” for KP.

Compliance with Ethical Standards

All experiments involving animals were performed in accordance with the guidelines set forth by the European Communities Council Directive of November 24, 1986 (86/609/EEC) and the protocol of experiments approved by the Animal Care and Use Committee of Kazan Federal University.


  1. 1.
    Gunnell, D., Eddleston, M., Phillips, M. R., & Konradsen, F. (2007). The global distribution of fatal pesticide self-poisoning: systematic review. BMC Public Health, 7(357).
  2. 2.
    Gunnell, D., Knipe, D., Chang, S. S., Pearson, M., Konradsen, F., Lee, W. J., & Eddleston, M. (2017). Prevention of suicide with regulations aimed at restricting access to highly hazardous pesticides: a systematic review of the international evidence. The Lancet Global Health, 5(10), e1026–e1037. Scholar
  3. 3.
    Dolgin, E. (2013). Syrian gas attack reinforces need for better anti-sarin drugs. Nature Medicine, 19(10), 1194–1195. Scholar
  4. 4.
    Patocka, J. (2017). What killed Kim Jong-nam? Was it the agent VX. Military Medical Science Letters, 86, 1–4. Scholar
  5. 5.
    Stone, R. (2018). U.K. attack puts nerve agent in the spotlight. Science, 359(6382), 1314–1315. Scholar
  6. 6.
    Weissman, B. A., & Raveh, L. (2008). Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicology and Applied Pharmacology, 232(2), 351–358. Scholar
  7. 7.
    Tattersall J (2016) Nicotinic receptors as targets for nerve agent therapy. In: Worek F (ed) Chemical warfare toxicology. Volume 2: Management of poisoning. The Royal Society of Chemistry, pp 82–119.
  8. 8.
    Malomouzh, A. I., & Nikolsky, E. E. (2018). Modern concepts of cholinergic neurotransmission at the motor synapse. Biochemistry (Moscow), Supplement Series A: Membrane and Cell Biology, 12(3), 209–222. Scholar
  9. 9.
    Petrov, K. A., Nikolsky, E. E., & Masson, P. (2018). Autoregulation of acetylcholine release and micro-pharmacodynamic mechanisms at neuromuscular junction: selective acetylcholinesterase inhibitors for therapy of myasthenic syndromes. Frontiers in Pharmacology, 9(766).
  10. 10.
    Petrov, K. A., Malomouzh, A. I., Kovyazina, I. V., Krejci, E., Nikitashina, A. D., Proskurina, S. E., Zobov, V. V., & Nikolsky, E. E. (2013). Regulation of acetylcholinesterase activity by nitric oxide in rat neuromuscular junction via N-methyl-D-aspartate receptor activation. The European Journal of Neuroscience, 37(2), 181–189. Scholar
  11. 11.
    Malomouzh, A. I., Petrov, K. A., Nurullin, L. F., & Nikolsky, E. E. (2015). Metabotropic GABAB receptors mediate GABA inhibition of acetylcholine release in the rat neuromuscular junction. Journal of Neurochemistry, 135(6), 1149–1160. Scholar
  12. 12.
    Nurullin, L. F., Nikolsky, E. E., & Malomouzh, A. (2018). Elements of molecular machinery of GABAergic signaling in the vertebrate cholinergic neuromuscular junction. Acta Histochemica, 120(3), 298–301. Scholar
  13. 13.
    Weiss, E. S. (1948). An abridged table of probits for use in the graphic solution of the dosage-effect curve. American Journal of Public Health and the Nation's Health, 38(1 Pt 1), 22–24. Scholar
  14. 14.
    Thiermann, H., Eyer, P., & Worek, F. (2010). Muscle force and acetylcholinesterase activity in mouse hemidiaphragms exposed to paraoxon and treated by oximes in vitro. Toxicology, 272(1–3), 46–51. Scholar
  15. 15.
    Petrov, K. A., Girard, E., Nikitashina, A. D., Colasante, C., Bernard, V., Nurullin, L., Leroy, J., Samigullin, D., Colak, O., Nikolsky, E., Plaud, B., & Krejci, E. (2014). Schwann cells sense and control acetylcholine spillover at the neuromuscular junction by α7 nicotinic receptors and butyrylcholinesterase. The Journal of Neuroscience, 34(36), 11870–11883. Scholar
  16. 16.
    Karalliedde, L., & Henry, J. A. (1993). Effects of organophosphates on skeletal muscle. Human & Experimental Toxicology, 12(4), 289–296. Scholar
  17. 17.
    Soukup, O., Jun, D., Tobin, G., & Kuca, K. (2013). The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors. Archives of Toxicology, 87(4), 711–719. Scholar
  18. 18.
    Worek, F., Thiermann, H., & Wille, T. (2016). Oximes in organophosphate poisoning: 60 years of hope and despair. Chemico-Biological Interactions, 259(Pt B), 93–98. Scholar
  19. 19.
    Froestl, W., Gallagher, M., Jenkins, H., Madrid, A., Melcher, T., Teichman, S., Mondadori, C. G., & Pearlman, R. (2004). SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochemical Pharmacology, 68(8), 1479–1487. Scholar
  20. 20.
    Nowak, G., Partyka, A., Pałucha, A., Szewczyk, B., Wierońska, J. M., Dybała, M., Metz, M., Librowski, T., Froestl, W., Papp, M., & Pilc, A. (2006). Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br Journal de Pharmacologie, 149(5), 581–590. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Arbuzov Institute of Organic and Physical ChemistryFRC Kazan Scientific Center of RASKazanRussia
  2. 2.Kazan Federal UniversityKazanRussia
  3. 3.Kazan Institute of Biochemistry and BiophysicsFRC Kazan Scientific Center of RASKazanRussia

Personalised recommendations